A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742
Latest Information Update: 13 May 2022
At a glance
- Drugs Elbasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 29 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.